Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

274 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Broadly Reactive Nanobody Targeting the H3 Hemagglutinin of the Influenza A Virus.
Shcheblyakov DV, Voronina DV, Favorskaya IA, Esmagambetov IB, Alekseeva IA, Korobkova AI, Ryabova EI, Derkaev AA, Kan VY, Dzharullaeva AS, Tukhvatulin AI, Bandelyuk AS, Shmarov MM, Logunov DY, Gintsburg AL. Shcheblyakov DV, et al. Among authors: gintsburg al. Acta Naturae. 2024 Jan-Mar;16(1):101-110. doi: 10.32607/actanaturae.27374. Acta Naturae. 2024. PMID: 38698957 Free PMC article.
Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response.
Mazunina EP, Gushchin VA, Kleymenov DA, Siniavin AE, Burtseva EI, Shmarov MM, Mukasheva EA, Bykonia EN, Kozlova SR, Evgrafova EA, Zolotar AN, Shidlovskaya EV, Kirillova ES, Krepkaia AS, Usachev EV, Kuznetsova NA, Ivanov IA, Dmitriev SE, Ivanov RA, Logunov DY, Gintsburg AL. Mazunina EP, et al. Among authors: gintsburg al. Front Immunol. 2024 Apr 16;15:1381508. doi: 10.3389/fimmu.2024.1381508. eCollection 2024. Front Immunol. 2024. PMID: 38690272 Free PMC article.
Major Role of S-Glycoprotein in Providing Immunogenicity and Protective Immunity in mRNA Lipid Nanoparticle Vaccines Based on SARS-CoV-2 Structural Proteins.
Bykonia EN, Kleymenov DA, Gushchin VA, Siniavin AE, Mazunina EP, Kozlova SR, Zolotar AN, Usachev EV, Kuznetsova NA, Shidlovskaya EV, Pochtovyi AA, Kustova DD, Ivanov IA, Dmitriev SE, Ivanov RA, Logunov DY, Gintsburg AL. Bykonia EN, et al. Among authors: gintsburg al. Vaccines (Basel). 2024 Apr 2;12(4):379. doi: 10.3390/vaccines12040379. Vaccines (Basel). 2024. PMID: 38675761 Free PMC article.
New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses.
Siniavin AE, Gushchin VA, Shastina NS, Darnotuk ES, Luyksaar SI, Russu LI, Inshakova AM, Shidlovskaya EV, Vasina DV, Kuznetsova NA, Savina DM, Zorkov ID, Dolzhikova IV, Sheremet AB, Logunov DY, Zigangirova NA, Gintsburg AL. Siniavin AE, et al. Among authors: gintsburg al. Antiviral Res. 2024 May;225:105871. doi: 10.1016/j.antiviral.2024.105871. Epub 2024 Mar 28. Antiviral Res. 2024. PMID: 38555022 Free article.
Synthesis and Antiviral Activity of Novel β-D-N4-Hydroxycytidine Ester Prodrugs as Potential Compounds for the Treatment of SARS-CoV-2 and Other Human Coronaviruses.
Darnotuk ES, Siniavin AE, Shastina NS, Luyksaar SI, Inshakova AM, Bondareva NE, Zolotov SA, Lubenec NL, Sheremet AB, Logunov DY, Zigangirova NA, Gushchin VA, Gintsburg AL. Darnotuk ES, et al. Among authors: gintsburg al. Pharmaceuticals (Basel). 2023 Dec 26;17(1):35. doi: 10.3390/ph17010035. Pharmaceuticals (Basel). 2023. PMID: 38256869 Free PMC article.
In Vitro Antiviral Activity of a New Indol-3-carboxylic Acid Derivative Against SARS-CoV-2.
Narovlyansky AN, Filimonova MV, Tsyshkova NG, Pronin AV, Grebennikova TV, Karamov EV, Larichev VF, Kornilayeva GV, Fedyakina IT, Dolzhikova IV, Mezentseva MV, Isaeva EI, Poloskov VV, Koval LS, Marinchenko VP, Surinova VI, Filimonov AS, Shitova AA, Soldatova OV, Sanin AV, Zubashev IK, Ponomarev AV, Veselovsky VV, Kozlov VV, Stepanov AV, Khomich AV, Kozlov VS, Ivanov SA, Shegai PV, Kaprin AD, Ershov FI, Gintsburg AL. Narovlyansky AN, et al. Among authors: gintsburg al. Acta Naturae. 2023 Oct-Dec;15(4):83-91. doi: 10.32607/actanaturae.26623. Acta Naturae. 2023. PMID: 38234608 Free PMC article.
Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period.
Fomina DS, Lebedkina MS, Iliukhina AA, Kovyrshina AV, Shelkov AY, Andreev SS, Chernov AA, Dolzhikova IV, Kruglova TS, Andrenova GV, Tukhvatulin AI, Shcheblyakov DV, Karaulov AV, Lysenko MA, Logunov DY, Gintsburg AL. Fomina DS, et al. Among authors: gintsburg al. Front Immunol. 2023 Oct 20;14:1259725. doi: 10.3389/fimmu.2023.1259725. eCollection 2023. Front Immunol. 2023. PMID: 37928549 Free PMC article. Clinical Trial.
274 results